Back to search
FDAFDA · Food and drugs·Recall number D-0226-2017

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01

Published December 28, 2016 · Recall initiated: December 15, 2016

Summary

FDA records drug Class II recall D-0226-2017, published December 28, 2016 and initiated December 15, 2016. Recalling firm: Amgen, Inc.; Status: Terminated; Reported quantity: 11,434 vials; Lot: Lot #1071559, 1071629; Exp. 05/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Potential cracks in glass vials

What to do

Voluntary: Firm initiated · Letter

Get an email if KYPROLIS has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
KYPROLIS
Manufacturer
Amgen, Inc.
Distributor
United States and Puerto Rico No foreign distribution.
Lot
Lot #1071559, 1071629; Exp. 05/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01 recalled?

Yes. FDA published recall D-0226-2017 on December 28, 2016. Reported hazard: Lack of Assurance of Sterility: Potential cracks in glass vials

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: KYPROLIS.